PPT-Metastatic HER2-Positive Breast Cancer: Treatment Selection

First Line and Beyond Moderator Joseph Gligorov MD PhD Head Cancer Coordination Center HUEP University Cancer Institute Sorbonne University Paris France Panelist Carlos H Barrios . Jennifer M. Matro, MD. Rena Rowan Breast Center. Abramson Cancer Center. University of Pennsylvania. Overview. What is metastatic breast . c. ancer (MBC)?. Who is at risk?. Subtypes of Breast Cancer. . Dr.Mina. . Tajvidi. Radiation . oncologist. . Fewer than 10 percent of women present with metastatic disease at the time of diagnosis. the majority of women who relapse after definitive therapy for early stage or locally advanced disease will do so with disseminated metastatic disease rather than an isolated local recurrence. ASCO-CAP Recommendations For HER2 Testing in Breast Cancer. Criteria For Reporting HER2 Test Results . as Positive. Criteria for Reporting HER2 Test Results . as Negative. Criteria for Reporting Equivocal Results . Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings Christy A Russell, MD Keck School of Medicine University of Southern California Metastatic Breast Cancer An Interactive Oncology Grand Rounds Series. Joyce O’Shaughnessy, MD. Chair, Breast Cancer Research Program. Baylor Charles A Sammons Cancer Center. Celebrating Women Chair in Breast Cancer Research. Julie R. Gralow, M.D.. Director, Breast Medical Oncology. Jill Bennett Endowed Professor of Breast Cancer. Professor, Global Health. University of Washington School of Medicine. Fred Hutchinson Cancer Research Center. Triple-Negative Breast Cancer. Jamie Carroll, APRN, MSN, CNP. Hope S . Rugo. , MD. . Disclosures for . Ms. Carroll. No financial interests or affiliations to disclose. Disclosures for Dr . Rugo. Contracted Research. in Development for . Breast Cancer. Sara A. Hurvitz, MD, FACP. Professor of Medicine. David Geffen School of Medicine, UCLA. Los Angeles, CA. William J. Gradishar, MD, FASCO, FACP. Betsy Bramsen Professor of Breast Oncology & Professor of Medicine. Breast Cancer . Elizabeth O’Reilly, MSN, MPH, ANP-BC. Sara . Hurvitz. , MD. Disclosures for . Ms. O’Reilly. No financial interests or affiliations to disclose. Disclosures for Dr . Hurvitz. Salary: . Bidstrup. Mrs B is a 49 . yo. woman who attended for a regular 3 weekly review and Herceptin dose. Intro. Dec 2000: . attended GP regarding lump that had been present in L) breast for 6/12. . Bx. - breast ca. ishtiaq. . FCPS R3 general surgery unit one UKSO . prof . tariq. . ghaffor. . sb. . . Objectives. Surgical Anatomy. Investigations. Diagnosis. Percent with Patients. Number of Patients (Median). ER-positive, HER2-negative breast cancer for whom you ordered a genomic assay. 92. 14. Metastatic ER-positive, HER2-negative . breast cancer. 96. 10. Jo Anne Zujewski, M.D.. June 2019. Thimphu. , Bhutan. Define the breast cancer. Is the cancer operable?. Stage 1: systemic therapy after surgery (and radiation if breast conservation). Stage 2: systemic therapy before or after therapy. breast. . cancer. . needs. . different. . therapeutic. . strategies. . than. HER-2 . enriched. . tumors. ?. Patrizia Vici. Cleopatra. TDM-1: . EMILIA. Verma. S ESMO 2012. (. Activity. . HR+.